Efficacy of Resveratrol in Depression

• Status: Completed
• Trial end date: 2019-09-18
• Target enrollment: 0
• Participant gender: All

Summary

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Russian Academy of Medical Sciences
• Collaborator: Russian Science Foundation
• Treatments: Resveratrol

Criteria

Inclusion Criteria (selectively):

• MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5);

• current depression.

Exclusion Criteria (selectively):

• serious or unstable disease;

• antidepressants intake.